Welcome to our dedicated page for Sagimet Biosciences news (Ticker: SGMT), a resource for investors and traders seeking the latest updates and insights on Sagimet Biosciences stock.
Sagimet Biosciences Inc. develops clinical-stage fatty acid synthase (FASN) inhibitors for diseases tied to dysfunctional metabolic and fibrotic pathways. Company news centers on denifanstat, an oral FASN inhibitor studied in metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne, and TVB-3567, a second oral FASN inhibitor for acne.
Recurring updates include clinical and preclinical data presentations, FASCINATE-2 analyses, regulatory and license-partner developments, financial results, capital-structure disclosures, executive leadership changes, inducement grants, shareholder matters, and investor conference participation.
Sagimet Biosciences (Nasdaq: SGMT) announced management will participate in two investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 at 10:00 AM ET and Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 9:20 AM ET.
Both fireside chats will be webcast in the Investors & Media section at www.sagimet.com, with archived replays available for 90 days after each live event.
Sagimet (Nasdaq: SGMT) announced Ascletis reported positive 52-week safety results from an open-label Phase 3 trial of ASC40 (denifanstat) 50 mg once daily in moderate-to-severe acne.
The 240-subject open-label study showed denifanstat generally well tolerated through up to 52 weeks, with dry eye (5.5%) and dry skin (5.2%) as the only TEAEs ≥5%; no denifanstat-related Grade 3/4 AEs, no denifanstat-related SAEs, and efficacy endpoints improved versus 12-week data.
Ascletis (HKEX:1672) announced positive topline results from a Phase III open-label safety study of denifanstat (ASC40), a once-daily oral FASN inhibitor for moderate-to-severe acne. The 240-patient, 40-week trial reported a favorable safety and tolerability profile with mostly grade 1–2 TEAEs, no ASC40-related grade 3–4 AEs, no ASC40-related SAEs, and no deaths.
Ascletis also referenced a prior 480-patient randomized, double-blind Phase III trial that met all primary and key secondary endpoints in June 2025, and noted that a New Drug Application for ASC40 was recently accepted by the China National Medical Products Administration.
Sagimet Biosciences (Nasdaq: SGMT) will present a poster at the 10th Annual MASH-TAG Conference held January 8-10, 2026 in Park City, Utah.
The poster reports a secondary analysis from the Phase 2b FASCINATE-2 trial showing that denifanstat elicited a significant ≥2-stage fibrosis improvement in F3 MASH patients and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients. Presenting author is Rohit Loomba, M.D., M.H.Sc. Poster number MASHTAG.2026.A23 will be presented on Saturday, January 10, 2026 at The Chateaux Deer Valley.
Sagimet Biosciences (NASDAQ: SGMT) reported positive Phase 1 pharmacokinetic (PK) results for a once-daily combination of denifanstat and resmetirom on Dec 18, 2025. The open-label, 2-cohort PK study (NCT07216313) enrolled 40 healthy adults to evaluate multiple- and single-dose PK, drug-drug interactions, safety, and tolerability. The combination was generally well-tolerated with no serious adverse events, no treatment discontinuations, and no clinically significant lab abnormalities. Sagimet plans to use these data to pursue a Phase 2 proof-of-concept efficacy trial in MASH with F4 fibrosis, aiming to initiate the study in 2H 2026, subject to regulatory consultation, and noted a global license agreement for resmetirom API forms to support a fixed-dose combination development.
Sagimet Biosciences (Nasdaq: SGMT) entered a global, exclusive license with TAPI for innovative forms of the resmetirom API to support Sagimet’s fixed‑dose combination (FDC) program combining resmetirom with denifanstat.
The company has an ongoing Phase 1 pharmacokinetic trial of the denifanstat‑resmetirom combination (first participants dosed in September 2025) with topline data anticipated by end of 2025. Sagimet expects to select one licensed resmetirom form for manufacture of a once‑daily FDC tablet and plans to use that FDC in a Phase 3 study; a Phase 2 in F4 MASH is estimated to start in H2 2026, subject to regulatory consultation.
Sagimet (Nasdaq: SGMT) announced that Ascletis’ parent company said China’s National Medical Products Administration accepted a New Drug Application (NDA) for denifanstat (ASC40) for the treatment of moderate to severe acne on Dec 10, 2025. Sagimet granted Ascletis an exclusive license for denifanstat in China while Sagimet retains development rights for MASH in the rest of world. The NDA filing reflects Ascletis’ Phase 3 trial in acne, in which denifanstat met all primary and secondary endpoints and was generally well tolerated.
Ascletis (HKEX:1672) announced on December 10, 2025 that the China National Medical Products Administration (NMPA) accepted its New Drug Application for denifanstat (ASC40), a once-daily oral FASN inhibitor for moderate-to-severe acne vulgaris.
The company said denifanstat completed Phase II (NCT05104125) and Phase III (NCT06192264) studies, and in Phase III met all primary, key secondary and secondary efficacy endpoints (ITT analysis) versus placebo with a favorable safety profile and no related Grade 3/4 adverse events or related serious adverse events. The Phase III results were presented at EADV on September 17, 2025. Ascletis holds exclusive Greater China rights under a license from Sagimet Biosciences (Nasdaq: SGMT).
Sagimet Biosciences (Nasdaq: SGMT) announced inducement option grants on December 9, 2025 in connection with hiring three new employees. The Compensation Committee approved an aggregate of 42,800 stock options under the Nasdaq Rule 5635(c)(4) inducement exception, to be granted on December 9, 2025.
The options use a Black‑Scholes‑determined grant value and have an exercise price equal to the closing price on December 9, 2025 as reported by the Nasdaq Global Market. Each option has a 10‑year term and vests over four years: 25% at the one‑year anniversary and the remainder monthly over 36 months, subject to continued service.
Sagimet Biosciences (Nasdaq: SGMT) will participate in the 8th Annual Evercore ISI Healthcare Conference on Tuesday, December 2, 2025 in Coral Gables, Florida.
Management will take part in a fireside chat at 12:55pm ET. A live webcast will be available in the company’s Investors & Media section at www.sagimet.com, with an archived replay accessible for 90 days after the event.